Institute of Functional Genomics (IGF)

EDUCATION

2009

Habilitation to Supervise Research (HDR) - University of Montpellier - France
1999

PhD - Biochemistry & Molecular Biology - University of Montpellier - France
1995

Master's degree - Health Biology - University of Montpellier - France

POSITIONS HELD

2023-

Senior Researcher at INSERM, Institute of Functional Genomics (IGF) - Montpellier - France
2002-2022

Junior Researcher at INSERM, Institute of Functional Genomics (IGF) - Montpellier - France
2000-2002

Postdoctoral fellow, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM) - Brussels - Belgium

HONORS / RESPONSABILITIES

Awards
2024-2026

Research and Doctoral Supervision grant (PEDR)
2020-2023

Research and Doctoral Supervision grant (PEDR)
2016

Member of the Inserm cross-cutting Program Microbiota
2013

Junior Faculty Award - AD/PD™ 2013 - The Alzheimer's & Parkinson's Conference
2012

Chercheuse d'avenir 2011 of the Languedoc Roussillon Region
2011

Soroptimist International (French Union) Medal
2010

France Alzheimer Research prize 2010
1997

Roche Bioscience Prize - Advances in Serotonin Receptor Research, San Francisco, USA

Duties
2023-

Neuroscience representative on the Board of the BioHealth Department of Univ. Montpellier
2015-2023

Scientific Board member of France Alzheimer association
2005-2010

Elected member of the IGF Unit Council
1997-

Member of the International Society for Serotonin Research (ISSR)
1997-

Member of the French Neuroscience Society

SKILLS / EXPERTISE

My areas of expertise cover neuropharmacology, G-protein coupled receptors (GPCRs), serotonin receptors and neurodegenerative diseases. In connection with a network of clinicians, chemists, and biotech companies I propose innovative strategies to cure Alzheimer's disease (α-secretase activation, Multi-Targeted drugs, biomarkers), based on a deep knowledge of molecular and cellular mechanisms induced by GPCRs in neuroprotection.

Member of the Inserm cross-cutting Program Microbiota, I currently explore the potential of gut microbiota modulation as a new therapeutic avenue against Alzheimer's disease.

Directory